Anke Heidemeier

Oberdürrbacher Str 6
Wuerzburg, BY 97080, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Ultra-High-Resolution Dual-Source Photon-Counting CT for Expanded Characterization of Pathophysiological Imaging Patterns in Multiple Myeloma.

Ultra-High-Resolution Dual-Source Photon-Counting CT for Expanded Characterization of Pathophysiological Imaging Patterns in Multiple Myeloma.

Journal: Investigative radiology

Published: May 05, 2026

Energy-resolved attenuation behaviour on dual-source photon-counting CT: Implications for quantitative assessment of femoral bone marrow in multiple myeloma.

Energy-resolved attenuation behaviour on dual-source photon-counting CT: Implications for quantitative assessment of femoral bone marrow in multiple myeloma.

Journal: European journal of radiology

Published: May 01, 2026

Reconstruction-kernel Dependence of Femoral Bone Marrow Attenuation in Whole-body Dual-source Photon-counting CT of Patients with Multiple Myeloma.

Reconstruction-kernel Dependence of Femoral Bone Marrow Attenuation in Whole-body Dual-source Photon-counting CT of Patients with Multiple Myeloma.

Journal: Academic radiology

Published: April 07, 2026

Whole-body Dual-source Photon-counting CT in Multiple Myeloma-The Value of Virtual Monoenergetic Imaging for Lesion Vitality Assessment.

Whole-body Dual-source Photon-counting CT in Multiple Myeloma-The Value of Virtual Monoenergetic Imaging for Lesion Vitality Assessment.

Journal: Investigative radiology

Published: May 15, 2025

Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition.

Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition.

Journal: Frontiers in oncology

Published: October 28, 2024

Erdheim-Chester disease with Rosai-Dorfman-like lesions: treatment with methotrexate, anakinra and upadacitinib.

Erdheim-Chester disease with Rosai-Dorfman-like lesions: treatment with methotrexate, anakinra and upadacitinib.

Journal: RMD open

Published: November 09, 2022

Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma.

Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma.

Journal: British journal of haematology

Published: February 25, 2022

Multi-parametric whole-body MRI evaluation discerns vital from non-vital multiple myeloma lesions as validated by 18F-FDG and 11C-methionine PET/CT.

Multi-parametric whole-body MRI evaluation discerns vital from non-vital multiple myeloma lesions as validated by 18F-FDG and 11C-methionine PET/CT.

Journal: European journal of radiology

Published: December 29, 2021

Efficacy of Zoledronic Acid in the Treatment of Nonmalignant Painful Bone Marrow Lesions: A Triple-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial (ZoMARS).

Efficacy of Zoledronic Acid in the Treatment of Nonmalignant Painful Bone Marrow Lesions: A Triple-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial (ZoMARS).

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Published: July 15, 2021

R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement.

R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement.

Journal: Journal of cancer research and clinical oncology

Published: May 09, 2021

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma.

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma.

Journal: International journal of immunopathology and pharmacology

Published: December 23, 2020

Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma.

Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma.

Journal: Nature medicine

Published: August 12, 2020

Showing 1-12 of 23

Last Updated: 09/26/2026